A Study of LY4355756 in Healthy Participants
Sponsor: Eli Lilly and Company • ClinicalTrials.gov ID: NCT07765498
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The purpose of the study is to assess how LY4355756 is absorbed by the body and how safe it is to healthy participants. There will be four inpatient stays at the clinical research unit (CRU). For Part A there will be 5 continuous days, Part B 22 continuous days, Part C 5 continuous days in each of the 3 periods, and Part D 18 continuous days in the CRU.
Interventions
-
LY4355756
(Drug)
Administered orally as capsule
-
LY4355756
(Drug)
Administered orally as tablet
-
Midazolam
(Drug)
Administered orally as liquid
Eligibility criteria
Conditions
Locations
- Fortrea Clinical Research Unit — Dallas, Texas, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record